The first-line immunotherapy anti-PD-(L)1 monotherapy strategy has become the new standard of care in locally advanced and metastatic NSCLC patients with high PD-L1 expression (Tumor Proportion Score [TPS]  ≥ 50%) and no targetable mutations (EGFR mutation or ALK translocations wild-type [WT]) [11, 20, 21]. Here, ALK is linked to non-small cell lung carcinoma.